Literature DB >> 27665205

Comparison of Outcomes of Transcatheter Aortic Valve Replacement Plus Percutaneous Coronary Intervention Versus Transcatheter Aortic Valve Replacement Alone in the United States.

Vikas Singh1, Alex P Rodriguez2, Badal Thakkar3, Nileshkumar J Patel2, Abhijit Ghatak4, Apurva O Badheka5, Carlos E Alfonso2, Eduardo de Marchena2, Rahul Sakhuja6, Ignacio Inglessis-Azuaje6, Igor Palacios6, Mauricio G Cohen2, Sammy Elmariah6, William W O'Neill7.   

Abstract

Transcatheter aortic valve replacement (TAVR) with percutaneous coronary intervention (PCI) has emerged as a less-invasive therapeutic option for high surgical risk patients with aortic stenosis and coronary artery disease. The aim of this study was to determine the outcomes of TAVR when performed with PCI during the same hospitalization. We identified patients using the International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes from the Nationwide Inpatient Sample between the years 2011 and 2013. A total of 22,344 TAVRs were performed between 2011 and 2013. Of these, 21,736 (97.3%) were performed without PCI (TAVR group) while 608 (2.7%) along with PCI (TAVR + PCI group). Among the TAVR + PCI group, 69.7% of the patients had single-vessel, 22.2% had 2-vessel, and 1.6% had 3-vessel PCI. Drug-eluting stents were more commonly used than bare-metal stents (72% vs 28%). TAVR + PCI group witnessed significantly higher rates of mortality (10.7% vs 4.6%) and complications: vascular injury requiring surgery (8.2% vs 4.2%), cardiac (25.4% vs 18.6%), respiratory (24.6% vs 16.1%), and infectious (10.7% vs 3.3%), p <0.001% for all, compared with the TAVR group. The mean length of hospital stay and cost of hospitalization were also significantly higher in the TAVR + PCI group. The propensity score-matched analysis yielded similar results. In conclusion, performing PCI along with TAVR during the same hospital admission is associated with higher mortality, complications, and cost compared with TAVR alone. Patients would perhaps be better served by staged PCI before TAVR.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27665205     DOI: 10.1016/j.amjcard.2016.08.048

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  To revascularize or not before transcatheter aortic valve implantation?

Authors:  Sergio Perez; Torin P Thielhelm; Mauricio G Cohen
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

Review 2.  Coronary Revascularisation in Transcatheter Aortic Valve Implantation Candidates: Why, Who, When?

Authors:  Davide Cao; Mauro Chiarito; Paolo Pagnotta; Bernhard Reimers; Giulio G Stefanini
Journal:  Interv Cardiol       Date:  2018-05

Review 3.  Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta-Analysis.

Authors:  Rafail A Kotronias; Chun Shing Kwok; Sudhakar George; Davide Capodanno; Peter F Ludman; Jonathan N Townend; Sagar N Doshi; Saib S Khogali; Philippe Généreux; Howard C Herrmann; Mamas A Mamas; Rodrigo Bagur
Journal:  J Am Heart Assoc       Date:  2017-06-27       Impact factor: 5.501

Review 4.  Bioprosthetic Aortic Valve Replacement in <50 Years Old Patients - Where is the Evidence?

Authors:  Amer Harky; Michael Man Yuen Suen; Chris Ho Ming Wong; Abdul Rahman Maaliki; Mohamad Bashir
Journal:  Braz J Cardiovasc Surg       Date:  2019-12-01

Review 5.  Coronary Assessment and Revascularization Before Transcutaneous Aortic Valve Implantation: An Update on Current Knowledge.

Authors:  Muhammad Sabbah; Thomas Engstrøm; Ole De Backer; Lars Søndergaard; Jacob Lønborg
Journal:  Front Cardiovasc Med       Date:  2021-05-21

Review 6.  Contemporary Revascularization Dilemmas in Older Adults.

Authors:  Sonali Kumar; Michael McDaniel; Habib Samady; Farshad Forouzandeh
Journal:  J Am Heart Assoc       Date:  2020-01-24       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.